Linked Life Data

21383284

Source:http://linkedlifedata.com/resource/pubmed/id/21383284

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2011-3-31
pubmed:databankReference
pubmed:abstractText
It is uncertain whether modest benefits from adjuvant chemotherapy in stage II colorectal cancer justify the toxicity, cost, and inconvenience. We investigated the usefulness of defective mismatch repair (dMMR), BRAF, and KRAS mutations in predicting tumor recurrence and sensitivity to chemotherapy.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Adaptor Proteins, Signal Transducing, http://linkedlifedata.com/resource/pubmed/chemical/BRAF protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/KRAS protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin, http://linkedlifedata.com/resource/pubmed/chemical/MLH1 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/MSH2 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/MutS Homolog 2 Protein, http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins B-raf, http://linkedlifedata.com/resource/pubmed/chemical/ras Proteins
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1527-7755
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1261-70
pubmed:dateRevised
2011-9-2
pubmed:meshHeading
pubmed-meshheading:21383284-Adaptor Proteins, Signal Transducing, pubmed-meshheading:21383284-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:21383284-Chemotherapy, Adjuvant, pubmed-meshheading:21383284-Colorectal Neoplasms, pubmed-meshheading:21383284-DNA Mismatch Repair, pubmed-meshheading:21383284-DNA Mutational Analysis, pubmed-meshheading:21383284-England, pubmed-meshheading:21383284-Fluorouracil, pubmed-meshheading:21383284-Humans, pubmed-meshheading:21383284-Immunohistochemistry, pubmed-meshheading:21383284-Leucovorin, pubmed-meshheading:21383284-MutS Homolog 2 Protein, pubmed-meshheading:21383284-Mutation, pubmed-meshheading:21383284-Neoplasm Staging, pubmed-meshheading:21383284-Nuclear Proteins, pubmed-meshheading:21383284-Odds Ratio, pubmed-meshheading:21383284-Patient Selection, pubmed-meshheading:21383284-Proto-Oncogene Proteins, pubmed-meshheading:21383284-Proto-Oncogene Proteins B-raf, pubmed-meshheading:21383284-Recurrence, pubmed-meshheading:21383284-Risk Assessment, pubmed-meshheading:21383284-Risk Factors, pubmed-meshheading:21383284-Time Factors, pubmed-meshheading:21383284-Tissue Array Analysis, pubmed-meshheading:21383284-Treatment Outcome, pubmed-meshheading:21383284-ras Proteins
pubmed:year
2011
pubmed:articleTitle
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
pubmed:affiliation
Leeds Institute of Molecular Medicine, Leeds University, United Kingdom.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study